Demographic and Clinical Characteristics of Responders and Non-Responders
| Characteristic | Responders N (%) n = 2386 | Non-responders N (%) n = 2286 | P-value* |
|---|---|---|---|
| Age (years) | 0.044 | ||
| <60 | 704 (29.5) | 712 (31.2) | |
| 60–64 | 511 (21.4) | 492 (21.5) | |
| 65–69 | 559 (23.4) | 464 (20.3) | |
| 70–74 | 349 (14.6) | 323 (14.1) | |
| ≥75 | 263 (11.0) | 294 (12.9) | |
| Missing | 0 (0.0) | 1 (0.0) | |
| Race/ethnicity | <0.0001 | ||
| Non-Hispanic White | 1850 (77.5) | 1405 (61.5) | |
| Non-Hispanic Black | 391 (16.4) | 691 (30.2) | |
| Hispanic | 32 (1.3) | 88 (3.9) | |
| Non-Hispanic Other | 0 (0.0) | 0 (0.0) | |
| Missing | 113 (4.7) | 102 (4.5) | |
| Insurance | 0.058 | ||
| Private | 1310 (54.9) | 1198 (50.9) | |
| Medicaid | 73 (3.1) | 102 (4.5) | |
| Medicare | 958 (40.2) | 921 (40.3) | |
| None/Other | 19 (0.8) | 20 (0.9) | |
| Missing | 26 (1.1) | 45 (2.0) | |
| Gleason score | 0.317 | ||
| <7 | 944 (39.6) | 901 (39.4) | |
| 7 | 953 (39.9) | 896 (39.2) | |
| >7 | 414 (17.4) | 348 (15.2) | |
| Missing | 75 (3.1) | 141 (6.2) | |
| Clinical tumor stage | 0.446 | ||
| Stage 1 | 1706 (71.5) | 1649 (72.1) | |
| Stage 2 | 574 (24.1) | 514 (22.5) | |
| Stage 3 | 58 (2.4) | 62 (2.7) | |
| Missing | 48 (2.0) | 61 (2.7) | |
| Treatment | |||
| Surgery | 1230 (51.6) | 1053 (46.1) | 0.496 |
| Missing | 386 (16.2) | 543 (23.8) | |
| Radiation therapy | 703 (29.5) | 602 (26.3) | 0.539 |
| Missing | 399 (16.7) | 537 (23.5) | |
| Hormone therapy | 326 (13.7) | 319 (14.0) | 0.122 |
| Missing | 423 (17.7) | 566 (24.8) | |
| Active Treatment | <0.001 | ||
| No | 393 (16.5) | 567 (24.8) | |
| Yes | 1897 (79.5) | 1620 (70.9) | |
| Missing | 96 (4.0) | 99 (4.3) |
↵* Using chi squared tests.